Robert Hallowell is a Respiratory physician affiliated with Harvard University. OpenAlex indexes 92 publications with 2,417 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142696
Telephone
617-726-1721Provider last certified this registry record 2 Sept 2020.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20253 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
32.8%Corticosteroid29.1%Prednisone100%Part D≥56 patientsProton pump inhibitor3.7%Omeprazole100%Part D≥11 patientsCancer & immunology
25.6%Kinase inhibitor17.8%Ofev100%Part D≥16 patientsCalcineurin inhibitor3.5%Tacrolimus100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
18.2%Short-acting sulfonamides7.9%Sulfamethoxazole-Trimethoprim100%Part D≥17 patientsMacrolide Antimicrobial6.1%Azithromycin100%Part D≥22 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patients With Inflammatory Bowel Disease Are at Increased Risk of Interstitial Lung Diseases
The American Journal of Gastroenterology
2025 - Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD
Respiratory Medicine and Research
2025 - Low forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease
European Respiratory Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Felipe Fregni, MD, MPH
Harvard University
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Elizabeth Buchbinder, MD
Harvard University
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”